Program Description
Hyperglycemia is a common and clinically significant adverse effect associated
with treatment with PI3K and AKT inhibitors in hormone receptor-positive (HR+)
breast cancer. Hyperglycemia occurs because the PI3K/AKT pathway, which is
targeted by these therapies to inhibit cancer cell growth, also plays a crucial
role in normal glucose metabolism. This webinar will provide oncology
pharmacists with a comprehensive overview of the PI3K/AKT/PTEN/mTOR pathway and
its role in HR+ breast cancer, as well as the mechanism of action for the PI3K
and AKT inhibitors. The pathophysiology of hyperglycemia induced by these
agents will be the focus of this discussion, equipping oncology pharmacists
with the knowledge to identify patients at risk and prepare for this common
adverse effect. If not promptly identified and managed, hyperglycemia can lead
to serious consequences, including dose interruptions or reductions that may
compromise the effectiveness of the anti-cancer treatment for patients. The
program will also review the incidence and severity of hyperglycemia as
observed in pivotal clinical trials as well as in real-world settings.
Target Audience: Oncology pharmacists
Type of Activity: Application
Release date: October 20, 2025
Expiration date: October 20, 2026
Learner level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the mechanism of action, mutation targets, and clinical indications for FDA-approved PI3K and AKT inhibitors
- Explain the pathophysiologic mechanisms by which PI3K and AKT inhibitors cause hyperglycemia and how these differ from other drug-induced hyperglycemia mechanisms
- Analyze real-world and clinical trial data on the incidence of hyperglycemia in patients receiving PI3K and AKT inhibitors
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here